Clinical Trials
14 trialsNCT02734537 2026-05-15
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Eastern Cooperative Oncology Group
Phase 2 Recruiting
NCT03529422 2025-07-20
Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT03854032 2025-06-06
Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck
Thomas Jefferson University
Phase 2 Active not recruiting
NCT03422536 2024-09-04
Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma
University of Arizona
Phase 2 Completed
NCT01172470 2023-11-29
Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer Patients
University of Chicago
Phase 2 Completed
NCT01185158 2023-11-29
A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma
University of Chicago
Phase 2 Completed
NCT01185171 2023-05-11
Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer
University of Chicago
Phase 2 Completed
NCT01414426 2021-01-14
Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions
University of Chicago
Phase 2 Completed
NCT02068157 2017-10-11
Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer
Roswell Park Cancer Institute
Phase 2 Terminated
NCT02196168 2017-05-03
Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01256385 2017-03-27
MAESTRO HN
National Cancer Institute (NCI)
Phase 2 Completed
NCT02007200 2016-10-24
Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00458978 2015-05-05
Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00100789 2012-10-01
S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
SWOG Cancer Research Network
Phase 2 Completed